Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00460 SIHUAN PHARM
RTNominal unchange 0.000 (0.000%)
Research Report

17/02/2021 10:42

Guotai Junan lifts Sihuan Pharmaceutical (00460) to HK$2.78

[ET Net News Agency, 17 February 2021] Guotai Junan International lifted its target
price for Sihuan Pharmaceutical (00460) to HK$2.78 from HK$1.15 and maintained its
"accumulate" rating.
The research house said the medical aesthetics platform is expected to serve as the
major source of revenue in the coming three years. Meanwhile, type A botulinum toxin for
injection (Letybo) marketing activities officially commenced in early February.
Guotai Junan said the market size of botulinum toxin products in China was RMB4 billion
in 2019, and it is expected to reach RMB11.5 billion in 2025, with a CAGR of around 19%.
It expects that Letybo will take up around 30% market share of botulinum toxin products in
the coming three years. (KL)

Back to Research Report

Remark: Real time quote last updated: 19/04/2024 07:42
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.